Menu

Study Linking Cell Phone Use to Cancer Stirs Debate

Exposing male rats to nonionizing radiation increased the animals’ risk of brain and heart tumors in a study, but the findings are far from conclusive.

May 27, 2016
Tanya Lewis

Sprague Dawley ratFLICKR, JEAN-ETIENNE MINH-DUY POIRRIERPartial results from a large-scale, peer-reviewed study conducted by scientists at the US National Toxicology Program (NTP) on the effects of cell phone-frequency radiation on rats and mice were released yesterday (May 26) on the preprint server bioRxiv. The NTP team found a 2.2 percent to 3.3 percent higher incidence of malignant gliomas in the brains and schwannomas in the hearts of male rats exposed to the radiation. But reviewers of the study and other scientists raised a number of important caveats.

“This is a controlled study and seems to have a solid study design,” Jill Barnholtz-Sloan of Case Western Reserve University School of Medicine, who was not involved in the study, wrote in an email to The Scientist. However, “there is not a clear dose response relationship from these data,” Barnholtz-Sloan said. “I also question the statistical power that they had to see these very small differences in incidence based on their sample size.”

NTP researchers exposed Sprague Dawley rats to 900 Megahertz GSM or CDMA radiofrequency radiation for nine hours a day throughout their lives, beginning in utero, at doses of 1.5, 3, or 6 Watts per kilogram (W/kg). (The US Federal Communications Commission limit for cellphone exposure in humans is 1.6 W/kg.) Each group contained 90 animals of each sex. Control groups of rodents were not exposed to radiation.

The researchers only observed a statistically significant increased risk of tumors among male rats exposed to the radiation. Not all of the animals developed tumors; some showed only hyperplastic changes, or tissue enlargement, in glial cells.

The control animals didn’t live as long as those that were exposed to the radiation—a result the researchers couldn’t explain. In addition, control animals didn’t develop any tumors, in contrast with controls from previous studies, which had a glioma incidence of 2 percent. “While [the authors’] trend analysis shows a significant change, overall this difference is not statistically significant,” Barnholtz-Sloan wrote. “In addition, the incidence rates in general are very low.”

Radiation exposure had no effect on the percent of dams littering, litter size, or sex distribution of pups. The researchers did observe a small, dose-dependent reduction in body weight among pups that were exposed to radiation in utero, although this difference lessened as the animals aged.

According to the US Food and Drug Administration, “the majority of studies published have failed to show an association between exposure to radiofrequency from a cell phone and health problems.”

The NTP group has yet to release the full results of its study, which include additional experiments on mice.

“At present . . . the NTP report does not provide reason to move from the current scientific consensus that mobile phone-like exposure does not impact health,” Rodney Croft, director of the Australian Centre for Electromagnetic Bioeffects Research at the University of Wollongong, said in a statement.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.